Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5580355 | 0.82 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL731664 | 0.81 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL5968591 | 0.81 | EGLN1 (0.39) | ALDH1A1 | |
| SCHEMBL733088 | 0.79 | ALDH1A1 (0.62) | ALDH1A1 | |
| SCHEMBL781568 | 0.79 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL942008 | 0.79 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL10972290 | 0.79 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL6738571 | 0.78 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL4098529 | 0.76 | MGAM (0.41) | ALDH1A1 | |
| SCHEMBL5069484 | 0.76 | LMNA (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111565707-A | Devices and methods for delivering therapeutics | 森玛治疗公司 | 2020-08-21 | — | — | CN | claimed |
| US-20050059137-A1 | Bio-support and preparing method of the same | MACROGEN INC. (KR) | 2005-03-17 | — | — | US | claimed |
| WO-2002033412-A1 | BIO-SUPPORT AND PREPARING METHOD OF THE SAME | MACROGEN INC. (KR) | 2002-04-25 | — | — | WO | claimed |
| EP-4629967-A1 | PERFLUORINATED MICELLES AND MEDICAL USES THEREOF | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121267-A1 | PERFLUORINATED MICELLES AND MEDICAL USES THEREOF. | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2024-06-13 | — | — | WO | disclosed |
| EP-4382091-A1 | PERFLUORINATED MICELLES AND MEDICAL USES THEREOF | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2024-06-12 | — | — | EP | disclosed |
| CN-117405878-B | Silica microsphere compound and preparation method and application thereof | 上海领检科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11905323-B2 | Recombinant chimeric protein for selectins targeting | Bracco Suisse (CH) | 2024-02-20 | — | — | US | disclosed |
| CN-117405878-A | Silica microsphere compound and preparation method and application thereof | 上海领检科技有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20220389080-A1 | RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING | BRACCO SUISSE SA (CH) | 2022-12-08 | — | — | US | disclosed |
| US-11370826-B2 | Recombinant chimeric protein for selectins targeting | BRACCO SUISSE SA (CH) | 2022-06-28 | — | — | US | disclosed |
| US-5719271-A | HYBRIDS; GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1998005687-A1 | MONOCLONAL ANTIBODY WHICH AGGLUTINATES E. COLI HAVING THE CS4-CFA/I FAMILY PROTEIN | DEPARTMENT OF THE ARMY, US GOVERNMENT (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0733066-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5543507-A | BONDING STRANDS OR ONE STRAND AT DIFFERENT SITES; RNA MIMICS FIXED IN SPATIAL CONFORMATION; NUCLEASE RESISTANT MIMICS OF BINDING RECEPTORS FOR NUCLEIC ACID-BINDING PROTEINS; 5-LIPOXYGENASE INHIBITORS; DIAGNOSIS; ANALYZING | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0661979-A4 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION. | MICROPROBE CORP (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0661979-A1 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION | MICROPROBE CORPORATION (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1995015979-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
| WO-1993003736-A1 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION | MICROPROBE CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5095097-A | Diagnostics | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1992-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905323-B2 | Recombinant chimeric protein for selectins targeting | SELPLG, SELL, SELE | ALDH1A1 2114/4885 |
| US-20220389080-A1 | RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING | SELPLG, SELL, SELE | ALDH1A1 2114/4885 |
| US-20050059137-A1 | Bio-support and preparing method of the same | EPCAM, STUB1, BST2 | ALDH1A1 31/4885 |
| US-11370826-B2 | Recombinant chimeric protein for selectins targeting | SELPLG, SELL, SELE | ALDH1A1 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.